Solfen-Tech®

Closing the analgesic gap, in the field, at scale

SOLFEN-TECH® PLATFORM PRODUCT

One platform. Multiple biological mechanisms.

Solfen-Tech® is a proprietary multimodal topical platform designed specifically for acute tissue injury.

Unlike systemic therapies that primarily reduce inflammatory amplification, Solfen-Tech® acts directly at the wound site to provide:

• Rapid local anaesthesia from approximately 30 seconds

• Sustained local drug exposure through a wound-depot effect

• Local vasoconstriction to prolong tissue residence

• Integrated antisepsis through cetrimide

Together these mechanisms address the earliest biological consequences of tissue injury while complementing systemic NSAID therapy, rather than replacing it.

The Proprietary Viscous Matrix

The Solfen-Tech® matrix binds active ingredients into a single, adherent topical formulation, ensuring sustained wound contact and simplified field application without systemic absorption.

Wound Depot: Sustained Anaesthesia

Lignocaine provides 30-second onset. Bupivacaine diffuses into peri-wound tissue and forms a sustained-release depot, maintaining local anaesthesia long after the procedure ends, covering the full analgesic gap.

Targeted Haemostasis

Induced vasoconstriction reduces bleeding at the wound site, improving procedural stability and extending the local anaesthetic activity window.

Infection Control: Preventing Secondary Pain Escalation

Cetrimide provides bactericidal antiseptic action at the wound site. By preventing secondary infection, it interrupts the inflammatory cascade that sustains pain beyond the acute procedural phase, a direct contribution to full-spectrum analgesia.

The Active Formulation Profile

The Solfen-Tech® matrix achieves full-spectrum pain control through four precisely calibrated active agents:

 

Lignocaine HCl (2%), fast-onset sodium channel blockade, providing anaesthesia within 30 seconds of application.

 

Bupivacaine HCl (0.5%), the wound depot agent. High lipophilicity drives tissue diffusion and sustained peri-wound accumulation, releasing analgesic effect continuously from the wound site long after application. This is the mechanism that extends pain control beyond the acute procedural window.

 

Adrenaline (0.1%), localised vasoconstriction that reduces bleeding, improves wound visibility, and extends the effective duration of both anaesthetic agents by slowing clearance from the application site.

 

Cetrimide (0.5%), bactericidal antiseptic that prevents post-procedural infection, interrupting the inflammatory cascade that would otherwise amplify and prolong pain beyond the procedural event itself.

Patented, four-way combination technology platform for wound care and pain mitigation

Click diagram to enlarge

INDICATIONS & SPECIES

One platform. Multiple species.

Tri-Solfen® is the only product with regulatory-grade evidence across cattle, sheep, pigs, and companion animals for multiple procedural indications.

Backed by an expanding foundation of clinical and field evidence across global livestock systems, Tri-Solfen® is actively approved in multiple major markets, with a robust pipeline of advancing global dossiers. This clinical validation serves as the engine for our regulatory footprint, securing the formal approvals that convert theoretical welfare standards into enforceable clinical practice—ultimately transforming discretionary use into structural, mandated demand.

CATTLE

Bovine procedures

  • Disbudding / Dehorning
  • Castration
  • Hoof lesions (in development)

SHEEP

Ovine procedures

  • Castration
  • Tail docking
  • Lamb marking

PIGS

Porcine procedures

  • Disbudding / Dehorning
  • Castration
  • Acute Surgical Wounds

DOGS

Companion animal

  • Superficial Wounds (in development)

HORSES

Equine procedures

  • Superficial Wounds

DISEASE PROGRAM

FMD Lesion Treatment

Tri-Solfen® treats oral and interdigital FMD lesions, restoring mobility and eating within 48 hours. Registered in Laos; registrations underway across Africa and Asia.

The Evidence & Regulatory Footprint

0bn

Global livestock population. Projected to reach 39 billion by 2030 (FAO)

>0bn

Animals undergo painful procedures annually (castration, dehorning, tail docking, mulesing)

0%

Of the global livestock population is affected by Foot and Mouth Disease (FAO).

<0bn

Animals undergo painful procedures annually (castration, dehorning, tail docking, mulesing)

0%

Of Australian wool growers are now using Tri-Solfen® for mulesing and husbandry procedures

0m+

Animals treated globally

0+

Peer-reviewed publications

It works

Evidence across cattle, sheep, pigs, and companion animals

0st

Registered topical analgesic/antiseptic approach used in FMD lesion management (Laos field program)

In use

Demonstrated use in multiple procedural and wound contexts

0+

Markets approved or registered

0+

Indications across species and procedures

Growth

Active expansion across Africa, Asia, Europe, and the Americas

3–5 days

To lesion recovery in FMD field trials, compared to significantly longer untreated baselines (Univ. of Sydney, 2019)

Platform Economics

A self-reinforcing model for global adoption and scale

Clinical Impact & Integration

System-Level Integration & Commercial Efficacy

Tri-Solfen® links welfare improvement directly to production outcomes. By accelerating wound healing, improving weight gain, and reducing post-procedural mortality, the platform delivers a measurable return on investment for producers operating under strict assurance frameworks.

Having treated over 210 million animals globally, the platform has proven its ability to integrate seamlessly into high-volume livestock workflows. Furthermore, its built-in antiseptic control aligns directly with global antimicrobial stewardship policies (WHO, WOAH) by significantly reducing the reliance on routine antibiotic use in commercial wound management.

The Moat & Investment Logic

A Compounding Platform Architecture

Protected by a robust global portfolio of 39+ granted patents extending through 2042, Tri-Solfen® is the lead commercial application of the broader Solfen-Tech® architecture. The platform’s pipeline is actively expanding to support multi-species integration, additional procedural indications, and geographically tailored formulations. By operating at the exact convergence of tightening welfare regulations, retailer compliance, and antimicrobial stewardship, Medical Ethics has created a self-reinforcing commercial engine. Regulation drives adoption, adoption yields clinical data, and data secures further regulatory integration—converting animal welfare science into scalable, enforceable, and economically measurable production standards.

Medical Ethics Tri-Solfen